Wugen raised $115 million to advance WU-CART-007, an allogeneic CAR-T therapy for rare T-cell cancers including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). The therapy uses gene editing to improve safety and scalability, enabling broader patient access to potentially life-saving treatment.
